Literature DB >> 6511154

Reduced high-density lipoprotein-cholesterol in power athletes: use of male sex hormone derivates, an atherogenic factor.

M Alén, P Rahkila.   

Abstract

The effect of androgenic steroids on plasma lipids was studied in seven power athletes who self-administered androgenic steroids on the average 45 mg/day during an 8-week strength training period. At the beginning of the study, no significant differences were noticed in HDL-cholesterol levels between the steroid users and the controls. After 8 weeks of strength training, the androgen users had reduced the HDL-cholesterol by 54% (from 1.47 to 0.67 mmol/l). The difference when compared to controls was highly significant (P less than 0.001). It was concluded that the use of androgenic steroids combined with strength training decreases serum HDL-cholesterol and thus may cause a higher risk for coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6511154     DOI: 10.1055/s-2008-1025929

Source DB:  PubMed          Journal:  Int J Sports Med        ISSN: 0172-4622            Impact factor:   3.118


  6 in total

Review 1.  Enhancement of athletic performance with drugs. An overview.

Authors:  J C Wagner
Journal:  Sports Med       Date:  1991-10       Impact factor: 11.136

2.  Adverse effect of the anabolic-androgenic steroid mesterolone on cardiac remodelling and lipoprotein profile is attenuated by aerobicz exercise training.

Authors:  Karina Fontana; Helena Coutinho Franco Oliveira; Marta Beatriz Leonardo; Carlos Alberto Mandarim-de-Lacerda; Maria Alice da Cruz-Höfling
Journal:  Int J Exp Pathol       Date:  2008-10       Impact factor: 1.925

3.  Lipid profile of body builders with and without self-administration of anabolic steroids.

Authors:  J Fröhlich; T Kullmer; A Urhausen; R Bergmann; W Kindermann
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1989

Review 4.  Effects of androgenic-anabolic steroids in athletes.

Authors:  Fred Hartgens; Harm Kuipers
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

Review 5.  Recent developments in the toxicology of anabolic steroids.

Authors:  S Graham; M Kennedy
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

Review 6.  Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease.

Authors:  Louise R Rodino-Klapac; Amanda M Haidet; Janaiah Kota; Chalonda Handy; Brian K Kaspar; Jerry R Mendell
Journal:  Muscle Nerve       Date:  2009-03       Impact factor: 3.217

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.